Last reviewed · How we verify
Atorvastatin Calcium 20mg, QD
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease in at-risk patients, Secondary prevention of cardiovascular events in patients with established coronary artery disease.
At a glance
| Generic name | Atorvastatin Calcium 20mg, QD |
|---|---|
| Sponsor | Kuhnil Pharmaceutical Co., Ltd. |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the mevalonate pathway responsible for de novo cholesterol synthesis in the liver. This inhibition leads to decreased intracellular cholesterol levels, upregulation of LDL receptors on hepatocytes, and increased clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Primary prevention of cardiovascular disease in at-risk patients
- Secondary prevention of cardiovascular events in patients with established coronary artery disease
Common side effects
- Myalgia (muscle pain)
- Elevated liver transaminases
- Headache
- Rhabdomyolysis (rare)
- Nausea
Key clinical trials
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes (PHASE4)
- The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques (PHASE4)
- Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy (PHASE2)
- Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439) (PHASE3)
- To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED) (PHASE3)
- Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis (PHASE3)
- Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin Calcium 20mg, QD CI brief — competitive landscape report
- Atorvastatin Calcium 20mg, QD updates RSS · CI watch RSS
- Kuhnil Pharmaceutical Co., Ltd. portfolio CI